DOCSLIB.ORG

FIRST GENE THERAPY RELATED DEATH JC Dumon, M. Sneyers Et

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FIRST GENE THERAPY RELATED DEATH JC Dumon, M. Sneyers Et Conseil de Biosécurité Section Biosécurité et Biotechnologie SECRETARIAT Dr W. Moens REPORT: FIRST GENE THERAPY RELATED DEATH J.C. Dumon, M. Sneyers et W. Moens CONTENTS Chapter I: The clinical case..........................................................................................................2 Introduction.............................................................................................................................2 Introduction.............................................................................................................................2 Partial ornithine transcarbamylase deficiency..........................................................................2 Clinical protocol......................................................................................................................2 Clinical case.............................................................................................................................3 Regulatory aspect....................................................................................................................4 Conclusion..............................................................................................................................4 References...............................................................................................................................5 Information on the death......................................................................................................5 « News » on the Internet......................................................................................................5 Notices and publications of the RAC/FDA..........................................................................7 Literature in appendix..........................................................................................................7 Chapter II: Implications...............................................................................................................8 Introduction.............................................................................................................................8 Clinical case history.................................................................................................................8 Reactions of the investigators and the RAC members to the announcement of this death........9 FDA and RAC Actions..........................................................................................................10 Creation of the Public Health Subcommittee of the US Senate..............................................12 Spontaneous stopping of gene therapy clinical trials.............................................................12 Ethical evaluation of gene therapy..........................................................................................13 Consequences in the USA.....................................................................................................14 References.............................................................................................................................14 Internet references.............................................................................................................14 ‘Paper’ references.............................................................................................................20 Section de Biosécurité et Biotechnologie Rue Juliette Wytsmanstraat, 14 - B 1050 Brussels - BELGIUM Tél: 32-2-642.52.93 | Fax: 32-2-642.52.92 | Email: [email protected] | Web server: http://biosafety.ihe.be 27/06/2000 -P 1/20- Chapter I: The clinical case Introduction Introduction During the month of December, we read in the literature (3-5) and learned via the Internet (1-2) of the death of a patient following the injection of an adenoviral vector, within the framework of a gene therapy clinical trial being run at Pennsylvania University. The Service of Biosafety and Biotechnology (SBB) and the Biosafety Council are obliged to issue expert advice regarding the authorisation of new protocols or amendments to the clinical protocols for gene therapy using this type of vector. The SBB thus addressed a letter to the American Recombinant DNA Advisory Committee (RAC) requesting further information about this death. In the absence of a response from the RAC, and despite the intervention of the American Embassy in Brussels, the SBB managed to gather the information available. The present report is a summary of this information. Partial ornithine transcarbamylase deficiency The pathology treated during the trial was partial ornithine transcarbamylase (OTC) deficiency; this is an enzyme of the mitochondrial matrix intervening in the urea cycle. This genetic pathology is a result of a mutation of the OTC gene, which reduces the hepatic production activities of OTC of 80% to 90% in hemizygotes. This hepatic deficiency in OTC develops in early childhood and leads to an accumulation of ammonia in the blood and the brain, leading to fatal hyper ammoniacal encephalopathy when there is no treatment. An accumulation of glutamin in the blood and an abnormally high excretion of urinary orotic acid also accompany the pathology. The standard treatment for this pathology is the administration of L-Citrulline and a strict protein diet. In some cases, a liver transplant can be considered (27). It should be noted that these patients are particularly vulnerable to all nature of infections (17). Gene therapy has recently become a therapeutic approach. Clinical protocol The clinical trial concerned was a phase I trial. It was being carried out at the hospital of Pennsylvania University (General Clinical Research Center) and at the Children’s National Medical Center; the principal investigator was Dr Mark L. Batshaw, co- investigators were the Section de Biosécurité et Biotechnologie Rue Juliette Wytsmanstraat, 14 - B 1050 Brussels - BELGIUM Tél: 32-2-642.52.93 | Fax: 32-2-642.52.92 | Email: [email protected] | Web server: http://biosafety.ihe.be 27/06/2000 -P 2/20- Drs James M. Wilson and Steven Raper. The Recombinant DNA Advisory Committee (RAC) had approved the trial on 4/12/95 under the reference ORDA 9512-139 (28) and ID UPSM- FDR001529. The clinical trial used an adenoviral vector deleted for the gene E1 of the adenovirus (transcription factor necessary for the replication of the adenovirus) and presenting a heat-sensitive mutation for the E2 gene. This vector expresses the human gene of OTC. Doses of 1X108 to 3X109 units of infectious particles/kg (2X1010 to 6X1011 viral particles/kg) were injected into one of the branches of the hepatic artery using a catheter. The particular criteria for including patients stipulated that the pathology be stable for at least one month, that the concentration of ammonia in the blood be lower than 70µM, and that the titre of anti-adenovirus neutralising antibodies be lower than 1280. It should be noted that among the exclusion criteria, it was recommended that patients do not have a viral hepatitis, AIDS or active tuberculosis (28). Clinical case Jesse Gelsinger, a patient aged 18, was the eighteenth patient who was voluntarily presented for inclusion in this clinical trial (14) under the reference OCT.019 (10). The patient received an injection of 3.8X1013 viral particles (3X109 units of infectious particles/kg) on 13 September 1999 (4). Post-injection, the patient rapidly developed a fever of 40°C (13) together with tachycardia, nausea, vomiting, and muscular pain (13). A hepatic impairment occurred (10), associated with a disseminated intravascular coagulation, which was in the process of improving within 48 hours (11). Unfortunately, after two days, the patient went into a coma (9) and developed respiratory distress (ARDS) requiring artificial ventilation (13). In view of the seriousness of the clinical scenario, which was developing, and the fact that the brain was impaired, the clinicians decided to cease artificial ventilation (18). Death was certified 4 days after having received the injection. At the autopsy, infiltration and inflammation of the lungs were observed (18), as well as anoxia of the kidneys and of the brain, with the spleen and the liver also being affected (16). In the bone marrow, there was also an absence of erythrocyte precursor cells, as well as an abnormality in the maturation of the precursor leukocyte lines (10), which could be linked to a viral infection by a parvovirus type B19 (17). The post mortem investigation led by the investigators excluded human error (8), and the specific analysis of the vector lot administered to this patient did not reveal any particular anomaly (10). In conclusion, and according to Dr James Wilson, the patient died from events occurring subsequent to receiving the injection of the vector (8) which generated a violent immune response (7) and an exaggerated inflammatory response (11) altering several organs and leading to death (5). Section de Biosécurité et Biotechnologie Rue Juliette Wytsmanstraat, 14 - B 1050 Brussels - BELGIUM Tél: 32-2-642.52.93 | Fax: 32-2-642.52.92 | Email: [email protected] | Web server: http://biosafety.ihe.be 27/06/2000 -P 3/20- Regulatory aspect As stipulated in the appendix M-VII-C of the Guidelines for research involving recombinant DNA molecules: May 1999 (24) published by the National Institute of Health (NIH) of the USA, the investigators of this clinical trial reported the death to the local Institutional Review Board, to the Institutional Biosafety Committee, to the NIH Office
Load more

Recommended publications
  • The Logic & Legitimacy of American Bioethics at The
    Doing the Right Thing: The Logic & Legitimacy of American Bioethics at the turn of the Millennium Item Type text; Electronic Dissertation Authors Leinhos, Mary Rebecca Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 02/10/2021 11:11:58 Link to Item http://hdl.handle.net/10150/193799 DOING THE RIGHT THING: THE LOGIC & LEGITIMACY OF AMERICAN BIOETHICS AT THE TURN OF THE MILLENNIUM by Mary Rebecca Leinhos ________________________ A Dissertation Submitted to the Faculty of the DEPARTMENT OF HIGHER EDUCATION In Partial Fulfillment Of The Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2006 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Dissertation Committee, we certify that we have read the dissertation prepared by Mary Rebecca Leinhos entitled Doing the Right Thing: The Logic & Legitimacy of American Bioethics at the Turn of the Millennium and recommend that it be accepted as fulfilling the dissertation requirement for the Degree of Doctor of Philosophy in Higher Education _____________________________________________________Date: Nov. 21, 2005 Jennifer Croissant _____________________________________________________Date: Nov. 21, 2005 Sheila Slaughter _____________________________________________________Date: Nov. 21, 2005 Gary Rhoades Final approval and acceptance of this dissertation is contingent upon the candidate’s submission of the final copies of the dissertation to the Graduate College. I hereby certify that I have read this dissertation prepared under my direction and recommend that it be accepted as fulfilling the dissertation requirement.
    [Show full text]
  • When Human Experimentation Is Criminal L
    Journal of Criminal Law and Criminology Volume 99 Article 3 Issue 1 Fall Fall 2008 When Human Experimentation is Criminal L. Song Richardson Follow this and additional works at: https://scholarlycommons.law.northwestern.edu/jclc Part of the Criminal Law Commons, Criminology Commons, and the Criminology and Criminal Justice Commons Recommended Citation L. Song Richardson, When Human Experimentation is Criminal, 99 J. Crim. L. & Criminology 89 (2008-2009) This Criminal Law is brought to you for free and open access by Northwestern University School of Law Scholarly Commons. It has been accepted for inclusion in Journal of Criminal Law and Criminology by an authorized editor of Northwestern University School of Law Scholarly Commons. 0091-4169/09/9901-0089 THE JOURNALOF CRIMINAL LAW & CRIMINOLOGY Vol. 99, No. I Copyright 0 2009 by Northwestern University, School of Law Printed in U.S.A. WHEN HUMAN EXPERIMENTATION IS CRIMINAL L. SONG RICHARDSON* Medical researchers engaged in human experimentation commit criminal acts seemingly without consequence. Whereas other actors who violate bodily integrity and autonomy are routinely penalized with convictions for assault, fraud, and homicide, researchers escape criminal punishment. This Article begins to scrutinize this undercriminalization phenomenon and provides a framework for understandingwhy researchers are not prosecuted for their crimes. It argues that their exalted social status, combined with the perceived social benefit of their research, immunizes them from use of the criminal sanction. Whether these constitute sufficient grounds to give researchers a pass from punishment is a significant question because the state's failure to act creates expressive harms. It displays attitudes towards victims and perpetrators that negatively affect the values of autonomy and dignity in medical research.
    [Show full text]
  • The Ethics of Social Research
    03-HesseBiber-4725.qxd 5/25/2005 7:53 PM Page 83 CHAPTER 3 THE ETHICS OF SOCIAL RESEARCH THE TUSKEGEE SYPHILIS STUDY The Tuskegee Syphilis Study was conducted by the United States Public Health Service (USPHS) beginning in 1932. The study examined untreated cases of latent syphilis in human subjects to determine the “natural course” of the disease. Three hundred and ninety nine black males from Tuskegee, Alabama, who already had late-stage syphilis, were recruited for this study along with a matched sample of 201 noninfected males. The subjects were not asked to provide their informed consent in order to participate in this project. Those infected with syphilis in the early 1930s were given the stan- dard treatment at that time, which consisted of administering heavy metals. However, those men participating in the study were, not treated. In fact, the doctor in charge of the study noted “everyone is agreed that the proper pro- cedure is the continuance of the observation of the negro men used in the study with the idea of eventually bringing them to autopsy” (Jones, 1993, p. 132). However, when antibiotics became available in the 1940s and it was evident that this treatment would improve a patient’s chances for recovery, antibiotic treatment was withheld from the infected subjects, even though the researchers knew that if left untreated the disease would definitely progress to increased disability and eventually early death. According to some reports, “on several occasions, the USPHS actually sought to pre- vent treatment” (Heintzelman, 1996, p. 49). The experiment lasted over four decades, and it was not until 1972, in large part prompted by exposure from 83 03-HesseBiber-4725.qxd 5/25/2005 7:53 PM Page 84 84–●–THE QUALITATIVE PARADIGM the national media, that government officials finally ended the experiment.
    [Show full text]
  • Download Printable Issue (PDF)
    S T A N F O R D MEDICINEMED Spring 2011 special report BIOETHICS NO EASY ANSWERS At midlife Ethicists roll up their sleeves Who will buy? Phony stem cell treatments for sale Gender X Born ambiguous Dead or alive? The tipping point between patient and organ donor Jesse’s legacy A conversation with Paul Gelsinger 11 years after his son’s death S T A N F O R D MEDICINE Spring 2011 high-res head shot A NEW WAy to see the brain’s connections It’s mind-boggling. A typical human brain contains about 200 billion neurons linked to one another via hundreds of trillions of tiny connections called synapses. These connections form the circuits behind thinking, feeling and moving — yet they’re so abundant and closely packed that getting a precise handle on what’s where has defied scientists’ best attempts. • But here comes a solution. Stephen Smith, PhD, professor of molecular and cellular physiology, and Kristina Micheva, PhD, a senior staff scientist in Smith’s lab, have invented a technique that quickly locates and counts the synapses in unprecedented detail, and reveals their variations. They described the imaging system, called “array tomography,” in the Nov. 18, 2010, issue of Neuron. • Attempting to map the cerebral cortex’s complex circuitry has been a fool’s errand up to now, Smith says. “We’ve been guessing at it.” Synapses in the brain are crowded so close together that they cannot be reliably resolved by even the best of traditional light microscopes, he says. • In particular, the cerebral cortex — a thin layer of tissue on the brain’s surface — is a thicket of prolifically branching neurons.
    [Show full text]
  • The Charlie Gard Case: British and American Approaches to Court Resolution of Disputes Over Medical Decisions
    OPEN Journal of Perinatology (2017) 37, 1268–1271 www.nature.com/jp COMMENTARY The Charlie Gard case: British and American approaches to court resolution of disputes over medical decisions JJ Paris1,2, J Ahluwalia3, BM Cummings4, MP Moreland5 and DJ Wilkinson6,7 Journal of Perinatology (2017) 37, 1268–1271; doi:10.1038/jp.2017.138; United States identified by the court as ‘Dr I.’ To finance the published online 19 October 2017 treatment the parents raised £1.3 million. The disagreement between the parents and the physicians in this case was not about cost, it was whether or not the experimental therapy ought to be tried on Charlie. The parents wanted it done. The physicians were For those whose bodies are riddled with disease, [Aclepius] opposed. They believed that continued intensive care and the did not attempt to prescribe a regimen in order to make proposed nucleoside treatment were ‘futile.’ their life a prolonged misery. Medicine isn’t intended for A British Court was petitioned to approve an order ‘that it is ’ fi such people ... even if they are richer than Midas. lawful, and in Charlie s best interests, for arti cial ventilation to be Plato, The Republic, Bk III. withdrawn ... and for his treating clinicians to provide him with palliative care only.’ The request was a direct challenge to the parent’s hopes. The case was assigned to Mr Justice Francis of the Family Division INTRODUCTION of the High Court. The judge made clear from the outset that ‘This ’ ‘ On 8 June 2017, the Supreme Court in the United Kingdom case is not about money.
    [Show full text]
  • Conflict of Interest in Medical Research, Education, and Practice
    Bernard Lo and Marilyn J. Field, Editors Committee on Conflict of Interest in Medical Research, Education, and Practice Board on Health Sciences Policy THE NATIONAL ACADEMIES PRESS 500 Fifth Street, N.W. Washington, DC 20001 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance. This study was supported by Contract No. N01-OD-4-2139, TO # 201 of the National Insti- tutes of Health, Contract No. 63229 of the Robert Wood Johnson Foundation, The Greenwall Foundation, the ABIM Foundation, Contract No. S07-2 of the Josiah Macy Jr. Foundation, Contract No. 1007182 of the Burroughs Wellcome Fund, and also the endowment fund of the Institute of Medicine, all contracts between the National Academies. Any opinions, find- ings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the organizations or agencies that provided support for the project. Library of Congress Cataloging-in-Publication Data Conflict of interest in medical research, education, and practice / Bernard Lo and Marilyn J. Field, editors ; Committee on Conflict of Interest in Medical Research, Education, and Practice, Board on Health Sciences Policy. p. ; cm. Includes bibliographical references and index. ISBN 978-0-309-13188-9 (hardcover) 1. Business and medicine.
    [Show full text]
  • The Modern Age of Informed Consent
    Pace University DigitalCommons@Pace Pace Law Faculty Publications School of Law 1-1-2006 The Modern Age of Informed Consent Barbara L. Atwell Elisabeth Haub School of Law at Pace University Follow this and additional works at: https://digitalcommons.pace.edu/lawfaculty Part of the Health Law and Policy Commons Recommended Citation Barbara L. Atwell, The Modern Age of Informed Consent, 40 U. Rich. L. Rev. 591 (2006), http://digitalcommons.pace.edu/lawfaculty/291/. This Article is brought to you for free and open access by the School of Law at DigitalCommons@Pace. It has been accepted for inclusion in Pace Law Faculty Publications by an authorized administrator of DigitalCommons@Pace. For more information, please contact [email protected]. THE MODERN AGE OF INFORMED CONSENT Barbara L. Atwell * Several years ago, Katherine, who at the time was a twenty- year-old Ivy League undergraduate, responded to an advertise- ment for egg donors. As a full-time college student, her financial resources were limited, and the promised $7,500 fee enticed her to respond. Katherine consented to the procedure despite the discom- fort involved and the numerous hormone injections that were re- q~ired.~She successfully donated nine eggs. Katherine subse- quently graduated from college and is now married with a successful career. She recently gave birth to her first child. She has stated repeatedly over the years that she regrets having do- nated her eggs. Katherine wonders whether there are other chil- dren who are biologically related to her and to her newborn child. She is also concerned about the long-term health impact of the hormone injections that were part of the egg donation pr~cedure.~ * Director, Health Law and Policy Program and Associate Professor of Law, Pace University School of Law; B.A., 1977, Smith College; J.D., 1983, Columbia University.
    [Show full text]
  • Ethical Concerns in Gene Transfer Research Objectives
    5/24/2011 Ethical Concerns in Gene Transfer Research James D. Hearn, J.D., LL.M., M.A. HCAA Research Compliance Conference University of Texas at Austin June 14, 2011 Objectives State of Gene Transfer Therapy - The what, how and the why Research Ethics – The rules of the game Ethical Considerations – The rationale behind the rules The Case of Jesse Gelsinger – What we now know Conflicts of Interest – Identification and neutralization Improving Subject Safety 1 5/24/2011 Name the Author “ To suggest that I acted or was influenced by money is really offensive to me. I don’t think about how my doing this work is going to make me rich. It’s about leadership and notoriety and accomplishment. Publishing in first rate journals. That’s what turns us on. You’ve got to be on the cutting edge and take risks if you are going to stay on top.” Who is Liam Heffernan? 2 5/24/2011 Liam Heffernan Two year old from Ireland Suffers from neurological disorder (Batten’s Disease) Batten’s disease is a fatal, inherited disorder of the nervous system that begins in childhood with early symptoms appearing between the ages of 2 and 4 when a previously normal child begins to develop vision problems or seizures. In some cases the early signs are subtle, taking the form of personality and behavior changes, slow learning, clumsiness, or stumbling. Over time, affected children suffer mental impairment, worsening seizures, and progressive loss of sight and motor skills. Eventually, children with Batten’s disease become blind, bedridden, and demented.
    [Show full text]
  • A Primer on the Law and Ethics of Treatment, Research, and Public Policy in the Context of Severe Traumatic Brain Injury Stacey A
    Annals of Health Law Volume 14 Article 3 Issue 1 Winter 2005 2005 A Primer on the Law and Ethics of Treatment, Research, and Public Policy in the Context of Severe Traumatic Brain Injury Stacey A. Tovino University of Houston Law Center William J. Winslade University of Texas Medical Branch Follow this and additional works at: http://lawecommons.luc.edu/annals Part of the Health Law and Policy Commons Recommended Citation Stacey A. Tovino & William J. Winslade A Primer on the Law and Ethics of Treatment, Research, and Public Policy in the Context of Severe Traumatic Brain Injury, 14 Annals Health L. 1 (2005). Available at: http://lawecommons.luc.edu/annals/vol14/iss1/3 This Article is brought to you for free and open access by LAW eCommons. It has been accepted for inclusion in Annals of Health Law by an authorized administrator of LAW eCommons. For more information, please contact [email protected]. Tovino and Winslade: A Primer on the Law and Ethics of Treatment, Research, and Public A Primer on the Law and Ethics of Treatment, Research, and Public Policy In the Context of Severe Traumatic Brain Injury Stacey A. Tovino, J.D.* and William J. Winslade, Ph.D., J.D. From the 1976 case of Karen Ann Quinlan' to the March 20, 2004, statement of Pope John Paul 11,2 physicians, lawyers, and theologians have struggled with the legal and ethical implications of treatment and public policy decisions in the context of devastating brain injury. Recent medical * Ms. Tovino is currently a Research Professor at the University of Houston Law Center.
    [Show full text]
  • Are Clinical Ethics Consultants in Danger? an Analysis of the Potential Legal Liability of Indmidual Clinical Ethicists
    ARE CLINICAL ETHICS CONSULTANTS IN DANGER? AN ANALYSIS OF THE POTENTIAL LEGAL LIABILITY OF INDMIDUAL CLINICAL ETHICISTS DAVID N. SONTAe INTRODUCTION In September 1999, eighteen-year-old Jesse Gelsinger tragically died while participating in a University of Pennsylvania gene transfer experiment.' The lawsuit that followed this unfortunate incident named as defendants not only the researchers involved but also re- nowned bioethicist Arthur Caplan. Although a hospital ethics com- mittee was named in a lawsuit more than ten years earlier,' there had t B.A. 1999, Washington University; M.Bioethics candidate 2003, University of Pennsylvania Medical School; J.D. candidate 2003, University of Pennsylvania Law School. I thank my wife, Sarah, for her constant love and support, but especially for being so patient during the writing and editing of this Comment. I would also like to thank Colin Diver, Anita Allen-Castellitto, Art Caplan, David Magnus, and Paul Root Wolpe for their insightful comments and recommendations. Finally, I am extremely grateful to Jodi Rosensaft, Michael Bacchus, Aiesha Hudson, and the rest of my col- leagues on the University of Pennsylvania Law Review for their hard work and dedication during the editing process. Alex Lapinski, In Aftermath of Gelsinger's Death, Tighter Rules for Tests, DAILY PENNSYLVANIAN, Nov. 6, 2001, http://www.dailypennsylvanian.com/vn-ews/display.v/ ART/2001/l1/06/3be7b02f2e42?inarchive=1. This type of experiment is more commonly known as "gene therapy." There has been much debate about the appro- priateness of this term, however, because it implies that the "experiment" or "research" will actually have a beneficial effect on the subject.
    [Show full text]
  • FDA Good Clinical Practice (GCP) Includes Both Laws – Binding Custom Or Practice of Community and Regulations – Implementation of the Law…
    Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Overview of Good Clinical Prac=ce and Ethical Principles 1 Objectives • Understand the moral obligation for doing human subject research RIGHT • Understand the history and scope of FDA oversight for drug development (and devices) • Know “Good Clinical Practice” (GCP) guidance documents 2 The Balancing Act of Clinical Research Scientific Advancement Pharmaceutical Sponsors Regulatory Oversight Product Development Federal Government Human Subject Protection 3 What is Most Important in Clinical Research? The subject’s Health Safety Welfare 4 Two Documents Important for Investigators and Research Staff to Review are Collectively Called Good Clinical Practice (GCP) FDA • Good Clinical Practice (GCP) is a United States set of laws for roles and responsibilities written in the Code of Federal Regulations (CFR) that are enforced by the FDA in conducting human subject research. They are in place to safeguard the public and ensure data integrity ICH International Conference on Harmonisation • ICH E6 document or GCP is an international ethical and scientific standard for designing, conducting, recording and reporting of trials involving participation of human subjects for a particular intervention of drug therapy or use of a device. Many drug manufacturers will train site staff with this document since they often conduct global clinical trials; not limited to the USA. 5 FDA Good Clinical Practice (GCP) Includes both Laws – binding custom or practice of community and Regulations – implementation of the law… …In order to maintain heath, safety and welfare of the people enrolled in the clinical trial and once the drug is approved and marketed to the general public.
    [Show full text]
  • Research Ethics: Where Are We, How Did We Get Here, and Where Are We Going?
    Shawna Benston April 18, 2019 Research Ethics: Where are we, How did we get here, and Where are we going? SHAWNA BENSTON, JD, MBE ASSISTANT DIRECTOR, RESEARCH COMPLIANCE EDUCATION OFFICE OF RESEARCH COMPLIANCE AND TRAINING Bioethics: a Model for Research Ethics 3 main areas of focus: Human biomedical ethics Animal ethics Environmental ethics Interdisciplinary, fluid approach 4/18/2019 1 Shawna Benston April 18, 2019 Four Principles of Biomedical Ethics Beauchamp and Childress: principlism in biomedical ethics (1) Respect for autonomy (2) Nonmaleficence (3) Beneficence (4) Social justice How did we get here? Why is research ethics important? 4/18/2019 Research Ethics – A Bit of History .1932‐1972: Tuskegee Syphilis Study .1932‐45: Horrific research performed by German scientists on concentration camp prisoners and by Japanese scientists on Chinese prisoners of war .1944‐1980s: US government sponsors secret research on effects of radiation on human beings; subjects not told they were participating in the experiments; subjects included cancer patients, pregnant women, and military personnel .1947: The Nuremberg Code for research on human subjects is adopted. The Allies use the document in the Nuremberg Trials to convict Nazi scientists of war crimes. .Watson and Crick discover the structure of DNA; they secretly obtain key x‐ray diffraction data from Rosalind Franklin without her permission. Watson and Crick shared the Nobel Prize in 1962; Franklin was not awarded a Nobel Prize because she died in 1953 from ovarian cancer (at age 37) and the prize is not awarded posthumously. https://www.niehs.nih.gov/resear4/18/2019 ch/resources/bioethics/timeline/index.cfm 2 Shawna Benston April 18, 2019 The Holocaust: Medical Experiments • Sterilization • Treatment of war wounds • Ways to counteract chemical weapons • Vaccines and drugs • Survival of harsh conditions • Physicians later charged at Nuremberg with crimes against humanity 4/18/2019 Nuremberg Code: 10 Points 1.
    [Show full text]